CTOs on the Move


 
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.gen9bio.com
  • 840 Memorial Drive Fifth Floor
    Cambridge, MA USA 02139
  • Phone: 617.250.8433

Executives

Name Title Contact Details

Similar Companies

NewNeural

NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerecin

Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat diseases of the brain. Cerecin`s development program leverages its extensive experience in lipid science to explore the potential therapeutic benefits of medium-chain triglycerides. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, Nestlé, and Wilmar, one of the world`s leading manufacturers of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.

Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs

Takeda Oncology

Takeda Oncology,, is a biopharmaceutical company based in Cambridge, Massachusetts.

Janpix

Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.